RANTES (CCL5) is a chemokine implicated in many human diseases. We previously showed that the transcription factor KLF13 controls the late (3-5 days after activation) expression of RANTES in T lymphocytes and that KLF13 itself is translationally regulated through the 5'-untranslated region of its mRNA. Here we show that KLF13 levels are further regulated by ubiquitination and degradation. KLF13 protein is undetectable in resting human T lymphocytes, but treatment with either proteosomal or lysosomal inhibitors increases KLF13 protein levels. GSK3β-mediated phosphorylation of KLF13 triggers the ubiquitination of KLF13 by the E3 ligase Fbw7γ, resulting in KLF13 protein degradation. Knockdown of either Fbw7γ or GSK3β by siRNA increases KLF13 expression in resting human T lymphocytes. In contrast, in murine T lymphocytes, KLF13 protein is abundant due to the absence of Fbw7γ. Treatment of unactivated human lymphocytes with lysosomal inhibitors stabilizes KLF13 protein resulting in an increase of RANTES mRNA and protein. Taken together, these studies demonstrate that tightly regulated control of both synthesis and degradation allows rapid changes in the level of KLF13 in human T lymphocytes.
Introduction from decreased apoptosis of lymphocytes due to increased expression of Bcl-X L 11 . Thus, KLF13 is a positive regulator of RANTES expression in T cells and a negative regulator of Bcl-X L , suggesting a dual role for KLF13 in inflammation in both inducing leukocyte recruitment and dampening the immune response via apoptosis.
Although KLF13 protein is not expressed in T lymphocytes until 3-5 days after activation, mimicking RANTES expression, KLF13 mRNA is present at all time points, including in resting T lymphocytes 12 . We previously showed that KLF13 is translationally regulated through its 5'-UTR in a cell type specific manner in T lymphocytes 12 . Overexpression of the translation initiation factor eIF4E increased KLF13 protein expression, while inhibition of Mnk1, which phosphorylates eukaryotic translation initiation factor (eIF)-4E, reduced KLF13 production, indicating capdependent translational regulation. KLF13 translation is further regulated by miR-125a, through its 3'UTR in T lymphocytes 13 . Additional post-translational modifications controlling KLF13 protein expression have not been reported.
A number of transcription factors involved in control of cell growth are unstable proteins targeted for degradation by the ubiquitin-proteasome system. The SKP1/CUL1/F-box (SCF) complex is among the best-studied multi-subunit RING-finger ligases which regulate cell cycle control proteins in many types of cells. The ubiquitin ligase F-box and WD repeat domain containing 7 (Fbw7) is a subunit of the SCF complex that regulates the cell cycle in T lymphocyte by degrading cell cycle regulators such as cyclin E and Notch 14 . We show here that KLF13 is ubiquitinated by Fbw7 and degraded in resting human T lymphocytes. In addition to translational regulation in activated T lymphocytes, a ubiquitin-dependent degradation pathway provides T For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From lymphocytes an additional mechanism for precise and rapid control of KLF13 expression in response to environmental stimuli. Because KLF13 has dual roles as an activator and a repressor in immune responses, steady-state levels of KLF13 are closely regulated by several mechanisms, including 1) cap dependent translation, 2) microRNA, and 3) ubiquitination mediated degradation.
Methods

T cell isolation and culture
Human and mouse tissues and blood were obtained using protocols approved by the NIH/NCI IRB and Animal Care and Use Committee. Human PBMCs were prepared as described 12 . PBMCs were cultured in RPMI 1640 supplemented with 10% FBS (Hyclone, Ogden UT), 100 U/mL penicillin/streptomycin, 2 mM L-glutamine, and 10 mM HEPES. T cells were enriched from PBMCs or freshly isolated mouse splenocytes by negative selection using a T cell enrichment Kit (StemCell Technologies, Vancouver, staining. For immunoblotting, cells were lysed in lysis buffer. After centrifugation, supernatants were subject to SDS-PAGE, and transferred to PVDF membranes. Protein bands were detected by ECL (GE Healthcare, Pittsburgh, PA).
Immunoprecipitation
For co-immunoprecipitation, HEK293T cells were transfected with plasmids expressing T7-tagged KLF13 or KLF13 and FLAG-tagged Fbw7 (WT, ∆ F, or ∆ F/R505A). Twentyfour hours after transfection, cells were lysed with lysis buffer, immunoprecipitated with anti-T7, anti-KLF13 or anti-FLAG antibodies, and subjected to immunoblotting.
Ubiquitination assays
KLF13 ubiquitination in vivo was detected by transfecting HEK293T cells with plasmids expressing KLF13 and/or HA-ubiquitin with or without plasmids expressing FLAGFbw7. Cells were lysed and immunoprecipitated with anti-KLF13 antibodies.
Ubiquitination of KLF13 was analyzed by Western blot analysis using anti-HA antibodies. The in vitro ubiquitnation assay was performed using S 35 Forty-eight hours after transfection, cell were lysed and FLAG-Fbw7γ was immunoprecipitated using anti-FLAG M2 agarose beads. The beads were washed four times with lysis buffer, twice in URB, and added to the ubiquitylation reactions.
Reactions were incubated at 30°C, stopped by addition of SDS loading buffer at the indicated times, resolved by SDS-PAGE, and analyzed by autoradiography.
siRNA
Fbw7 isoform-specific siRNAs, which were previously described (14) , and a universal negative control for siRNA were obtained from Integrated DNA Technologies (Coralville, IA). GSK3β-depleting SMARTpool siRNA oligonucleotides and nontargeting siRNA oligonucleotides were purchased from Dharmacon (Lafayette, CO).
Freshly isolated human T cells were transfected with siRNAs using 96-well shuttle Nucleofector (Lonza, Basel, Switzerland) according to the manufacturer's directions.
Real-Time PCR
Total RNA was isolated from resting or anti-CD3/anti-CD28 antibody-activated human T cells after 1, 2, 3, and 5 days with the RNeasy kit with genomic DNA elimination step by DNase I treatment, according to the manufacturer's protocol (Qiagen, Valencia, CA).
Total RNA (1 μ g) was used for reverse transcription to cDNAs using reverse transcriptase from Promega (Madison, WI). Real-time quantitative PCR was performed using SYBR Green Supermix Kit (Applied Biosystems). Relative expression of KLF13 or Fbw7 isoforms was normalized to β-glucuronidase or HPRT expression. Primers were designed as described 10 ; hKLF13 (forward: 5'-GTTTACGGGAAATCTTCGCA-3', 
Immunohistochemistry
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From KLF13 immunohistochemistry was performed on 5-μm thick paraffin-embedded sections using goat anti-KLF13 antibody (Santa Cruz Biotechnology). Antigen retrieval for deparaffinized tissue sections were performed in citrate buffer for 20 min with a steamer.
Following blocking of endogenous peroxidase, paraffin-embedded sections were submitted to immunohistochemistry using the Vectastain Elite ABC system (Vector Laboratories, Burlingame, CA). 
In vitro kinase assay
Cell Staining and Flow Cytometry
PBMCs from 4 donors were treated for 16 h with or without concanamycin A (1 μg/mL) and stained for surface expression of FITC-CD3 and PE-CD56 (BD Bioscience). Cells were then permeabilized with BD Cytofix/Cytoperm and stained with APC-VL1 (RANTES, eBioscience, San Diego, CA). Mean fluorescence was analyzed using FlowJo software (Tree Star, Ashland, OR).
Results
KLF13 expression is differentially regulated in mouse and human T lymphocytes
To compare KLF13 expression in the human and mouse, immunohistochemistry was performed using mouse and human tissues as well as specimens from Klf13 -/-mice 11 .
KLF13 is highly expressed in normal mouse thymus and spleen ( Figure 1A , B), while KLF13 is minimally detected in human lymph node ( Figure 1C , left panel) but is highly expressed in tonsil ( Figure 1C , right panel). Western blot analysis confirmed that KLF13
protein is highly expressed in both resting and activated mouse T lymphocytes ( Figure   2A ) but only in activated human T lymphocytes ( Figure 2B ). KLF13 mRNA levels decreased to some extent after activation of mouse T cells ( Figure 2C ) but remained constant in human T cells ( Figure 2D ). We previously showed that this distinct kinetic of human KLF13 expression is partially due to the eIF4E-dependent translational regulation 12 . To examine whether proteasome-mediated protein degradation also is involved in regulating levels of KLF13, mouse and human T cells were treated with MG-132 or lactacystin. These inhibitors increased KLF13 protein in human T cells ( Figure 2E ) but did not affect KLF13 levels in murine T cells ( Figure 2F ).
Fbw7 catalyzes KLF13 ubiquitination
Sequence analysis showed that KLF13 contains four potential CDC4-phosphodegron Fbw7∆F/R505A prevents the enzyme-substrate interaction 16 . As expected, KLF13 is coimmunoprecipitated with Fbw7∆F, but not with Fbw7∆F/R505A ( Figure 3C ), indicating that KLF13 interacts with Fbw7 through its known substrate binding domain.
Phosphorylation of serine or threonine residues in CPD domains is critical to the interaction between Fbw7 and its substrates 17 . There are six possible phosphorylation sites in the four candidate CPD sites in KLF13 ( Figure 3A ). To identify the responsible CPD(s) in KLF13, we individually mutated these six serine residues to glycine in KLF13 (S107G, S119G, S123G, S279G, S283G, and S287G), and performed a coimmunoprecipitation assay in HEK293T cells. S119G and S123G mutants fail to interact with Fbw7 while wild type (WT) and the remaining KLF13 mutants interact with Fbw7
( Figure 3D ). This finding indicates that the second CPD (residues 119-123, SPAWS) is responsible for KLF13 interaction with Fbw7. There are three isoforms of Fbw7 (α, β, and γ) that result from alternative splicing 18 . Fbw7α and γ are mainly localized in the nucleus while Fbw7β is localized in the cytoplasm 19 . To examine whether Fbw7 facilitates ubiquitination of KLF13, an in vivo ubiquitination assay was performed using HEK293T cells transfected with plasmids expressing KLF13, FLAG-tagged Fbw7α or γ,
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From and HA-tagged ubiquitin. Poly-ubiquitination was observed in cells transfected with plasmids expressing KLF13 and ubiquitin. Moreover, ubiquitination of KLF13 was enhanced when the cells were co-transfected with Fbw7γ but not with Fbw7α ( Figure   3E ), demonstrating that KLF13 is a substrate of Fbw7 and its ubiquitination is dependent on Fbw7γ expression rather than Fbw7α.
Fbw7γ regulates KLF13 ubiquitination in human T lymphocytes
The expression kinetics of the three isoforms Figure 5A ). However, proteasomal or lysosomal inhibitors had only a minimal effect on KLF protein levels in activated T cells ( Figure 5B ). GSK3β is often the priming kinase for targets of Fbw7. Therefore we asked whether GSK3 kinase inhibitors can also stabilize KLF13 protein in human T lymphocytes. KLF13 protein was stabilized to a similar extent by MG132 or by GSK-3 or GSK-3β inhibitors. However, no stabilization was observed using a p38 inhibitor ( Figure 5C ). These findings suggest that GSK3β is involved in Fbw7-mediated regulation of KLF13 expression. To further investigate this, GSK3β was knocked down in resting human T cells using GSK3β specific siRNA or a nontargeting control siRNA ( Figure 5D ). Western blot confirmed the loss of GSK3β protein and a corresponding increase in KLF13 protein. That GSK3β does in fact phosphorylate KLF13 was shown in an in vitro phosphorylation assay ( Figure 5E ). Recombinant GSK3β was able to phosphorylate recombinant GST-KLF13 but not recombinant GST. Finally, the role of Fbw7γ and GSK3β in ubiquitination of KLF13 was directly confirmed by an in vitro ubiquitination assay. Ubiquitination of KLF13 protein is directly catalyzed by Fbw7γ and further enhanced by GSK3β-mediated phosphorylation ( Figure 5F ). showed markedly reduced viability.
Discussion
We first described KLF13 as RANTES Factor of Late Activated T Lymphocytes (RFLAT) -1 9 . Although rel proteins regulate RANTES expression in most cell types, the "late" expression in T lymphocytes is regulated by a large transactivating complex composed of MAPK Nemo-like kinase, p300/CBP, PCAF and the ATPase BRG-1 10 ,
with KLF13 serving as its lynchpin 21 . KLF13 protein, like RANTES, is not expressed in T cells until 3-5 days after activation. Intriguingly, however, mRNA for KLF13 is expressed at the same level in both resting and activated T cells. We previously showed that this discrepancy between mRNA and protein expression is in part due to translational regulation in a T cell specific manner 12 . In this study we show that human KLF13 protein expression kinetic is different from that of mouse, and that degradation of KLF13
via Fbw7-mediated ubiquitination plays a major role in human T lymphocytes.
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Other members of the KLF family, including KLF1, 2, 4, 5, 6, and 10, are known to be ubiquitinated and degraded by a proteasome-dependent pathway [22] [23] [24] [25] [26] [27] , indicating that ubiquitination is a general mechanism for controlling expression of KLF proteins. Of special interest, KLF2 is ubiquitinated and degraded upon T cell activation, the inverse expression profile compared to KLF13. We recently stressed the yin-yang relationship of KLF13 and KLF2 expression and function in T lymphocytes 28 . . Although it is possible that, like cyclin E, KLF13 ubiquitination requires both the α and γ isoforms of Fbw7, the extremely high levels of Fbw7α make the γ isoform the limiting factor in the system. The expression level of Fbw7γ is much lower than Fbw7α in human T lymphocytes and is not detectable in murine T cells. Fbw7α mRNA is expressed at much higher levels than either Fbw7β or Fbw7γ in most if not all human cell lines and primary cells 36 . It has been shown that Fbw7α mRNA is present in all tissues whereas Fbw7β mRNA is detected only in brain and testis, and Fbw7γ mRNA is found only in heart and skeletal muscle in mouse 38 . We propose a schematic view of the complicated regulation of KLF13 and RANTES expression in T lymphocytes (Figure 7 ). RANTES expression in T lymphocytes is controlled by a complex mechanism in which KLF13 is a key.
KLF13 was stabilized by proteasome or lysosomal inhibitors in resting T cells but not in
Translational regulation occurs at the 5' untranslated region (UTR) of KLF13 mRNA and is controlled by the translation initiation complex and in particular, both the amount and phosphorylation of eIF4E. Of note, eIF4E levels are also increased after T cell activation
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From 12 . The 3' UTR of KLF13 mRNA is also translationally regulated by miRNA 125a 13 .
Our work here shows that protein degradation due to ubiquitination also contributes to the expression patterns of KLF13 in T cells. In the resting state, KLF13 expression is suppressed by GSK3β and Fbw7-mediated ubiquitination dependent protein degradation.
After T cell activation both Fbw7γ expression is reduced and GSK3β activity is inhibited, resulting in an increase in KLF13 expression and in turn RANTES levels. Our findings provide another piece in the biologic puzzle of the "late" expression of RANTES in T lymphocytes and may prove to be of clinical relevance if this pathway can be specifically targeted. 
